Paper No. ___
`Date Filed: Jan. 30, 2017
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`AMERIGEN PHARMACEUTICALS LIMITED
`ARGENTUM PHARMACEUTICALS LLC,
`Petitioner
`
`v.
`
`JANSSEN ONCOLOGY, INC.,
`Patent Owner
`
`________________
`
`Case IPR2016-002861
`Patent 8,822,438 B2
`
`________________
`
`
`JANSSEN ONCOLOGY, INC.’S UPDATED EXHIBIT LIST
`
`
`
`
`
`
`
`
`
`
`1 Case IPR2016-01317 has been joined with this proceeding.
`
`
`Date Filed: Jan. 30, 2017
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`AMERIGEN PHARMACEUTICALS LIMITED
`ARGENTUM PHARMACEUTICALS LLC,
`Petitioner
`
`v.
`
`JANSSEN ONCOLOGY, INC.,
`Patent Owner
`
`________________
`
`Case IPR2016-002861
`Patent 8,822,438 B2
`
`________________
`
`
`JANSSEN ONCOLOGY, INC.’S UPDATED EXHIBIT LIST
`
`
`
`
`
`
`
`
`
`
`1 Case IPR2016-01317 has been joined with this proceeding.
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`Pursuant to 37 C.F.R. § 42.63(e), Petitioner, Janssen Oncology, Inc. hereby
`
`submits a current list of its exhibits.
`
`Exhibit
`
`JSN 2001
`
`Description
`
`Declaration of David T. Pritikin in Support of Motion to Appear
`
`Pro Hac Vice
`
`JSN 2002
`
`Declaration of Bindu Donovan in Support of Motion to Appear Pro
`
`Hac Vice
`
`JSN 2003
`
`Remington – The Science and Practice of Pharmacy, 20th ed., pp.
`
`1363-1370 (2000)
`
`JSN 2004
`
`Rumohr and Chang, “Current chemotheratpeutic approaches for
`
`androgen-independent prostate cancer,” Current Opinion in
`
`Investigational Drugs, 7(6):529-533 (2006)
`
`JSN 2005
`
`Declaration of Professor Ian Judson, dated June 29, 2015, cited in
`
`the Opposition of European Patent 2 061 561
`
`JSN 2006
`
`Clinical Cancer Research Peer Review letter to Judson, dated May
`
`12, 2003
`
`JSN 2007
`
`Burgess and Roth, “Changing Perspectives of the Role of
`
`Chemotherapy in Advanced Prostate Cancer,” Urol. Clin. N. Am.,
`
`33:227-236 (2006)
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`Exhibit
`
`JSN 2008
`
`Description
`
`Strother et al., “Novel cytotoxic and biological agents for prostate
`
`cancer: Where will the money be in 2005?,” European Journal of
`
`Cancer, 41:954-964 (2005)
`
`JSN 2009
`
`Hadaschik et al., “Novel targets and approaches in advanced
`
`prostate cancer,” Current Opinions Urology, 17:182-187 (2007)
`
`JSN 2010
`
`Papatsoris et al., Novel Biological Agents for the Treatment of
`
`Hormone-Refractory Prostate Cancer (HRPC), Current Medicinal
`
`Chemistry, 12:277-296 (2005)
`
`JSN 2011
`
`Armstrong and Carducci, “New drugs in prostate cancer,” Current
`
`Opinions Urology, 16:138-145 (2006)
`
`JSN 2012
`
`Duc et al., “In vitro and in vivo models for the evaluation of potent
`
`inhibitors of male rat 17α-hydroxylase/C17,20-lyase,” Journal of
`
`Steroid Biochemistry & Molecular Biology, 84:537-542 (2003)
`
`JSN 2013
`
`Boehringer-Ingelheim-BTG Press Release – “NEW TREATMENT
`
`FOR PROSTATE CANCER UNDER DEVELOPMENT,” dated
`
`May 22, 1996
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`Exhibit
`
`JSN 2014
`
`Description
`
`Attard et al., “Phase I Clinical Trial of a Selective Inhibitor of
`
`CYP17, Abiraterone Acetate, Confirms That Castration-Resistant
`
`Prostate Cancer Commonly Remains Hormone Driven,” Journal of
`
`Clinical Oncology, 26(28):4563-4571 (2008)
`
`JSN 2015
`
`Attard et al., “Selective Inhibition of CYP17 With Abiraterone
`
`Acetate Is Highly Active in the Treatment of Castration-Resistant
`
`Prostate Cancer,” Journal of Clinical Oncology, 27(23):3742-3748
`
`(2009)
`
`JSN 2016
`
`Danila et al., “Phase II Multicenter Study of Abiraterone Acetate
`
`Plus Prednisone Therapy in Patients With Docetaxel-Treated
`
`Castration-Resistant Prostate Cancer,” Journal of Clinical
`
`Oncology, 28(9):1496-1501 (2010)
`
`JSN 2017
`
`Ryan et al., “Phase II Study of Abiraterone in Chemotherapy-Naïve
`
`Flare Discordant with Serologic Response Metastatic Castration-
`
`Resistant Prostate Cancer Displaying Bone,” Clinical Cancer
`
`Research, 17:4854-4861 (2011)
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`Exhibit
`
`JSN 2018
`
`Description
`
`Jubelirer and Hogan, “High Dose Ketoconazole For The Treatment
`
`Of Hormone Refractory Metastatic Prostate Carcinoma: 16 Cases
`
`And Review Of The Literature,” The Journal of Urology, 142:89-
`
`91 (1989)
`
`JSN 2019
`
`Public Citizen Press Room Release – “Antifunal Treatment Should
`
`Be Taken Off the Market, Public Citizen Tells FDAD,” dated
`
`February 24, 2015
`
`JSN 2020
`
`Williams et al., “Objective Responses to Ketoconazole Therapy in
`
`Patients with Relapsed Progressive Prostatic Cancer,” British
`
`Journal of Urology, 58:45-51 (1986)
`
`JSN 2021
`
`Boumpas et al., “Glucocorticoid Therapy for Immune-mediated
`
`Diseases: Basic and Clinical Correlates,” Ann. Internal Medicine,
`
`119:1198-1208 (1993)
`
`JSN 2022
`
`Debruyne and Witjes, “Ketoconazole High Dose (H.D.) In The
`
`Management Of Metastatic Prostatic Carcinoma,” The Journal of
`
`Urology, 135(4, pt.2):203A, Abstract 397 (1986)
`
`JSN 2023
`
`Herr and Pfitzenmaier, “Glucocorticoid use in prostate cancer and
`
`other solid tumours: implications for effectiveness of cytotoxic
`
`treatment and metastases,” The Lancet, 7:425-430 (2006)
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`Exhibit
`
`JSN 2024
`
`Description
`
`Krishnan et al., “A Glucocorticoid-Responsive Mutant Androgen
`
`Receptor Exhibits Unique Ligand Specificity: Therapeutic
`
`Implications for Androgen-Independent Prostate Cancer,”
`
`Endocrinology, 145:1889-1900 (2002)
`
`JSN 2025
`
`Conde and Aronson, “Risk factors for male osteoporosis,” Urologic
`
`Oncology, 21:380-383 (2003)
`
`JSN 2026
`
`Notice of Termination of Preprocessing of Ex Parte Reexamination
`
`Request
`
`JSN 2027
`
`Declaration of S. Isaac Olson in Support of Motion to Appear Pro
`
`Hac Vice
`
`JSN 2028
`
`Reserved
`
`JSN 2029
`
`Reserved
`
`JSN 2030
`
`Reserved
`
`JSN 2031
`
`Reserved
`
`JSN 2032
`
`Reserved
`
`JSN 2033
`
`Press Release 1/26/2016
`
`JSN 2034
`
`Press Release 1/21/2014
`
`JSN 2035
`
`Press Release 1/20/2015
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`Exhibit
`
`JSN 2036
`
`Reserved
`
`Description
`
`
`JSN 2037
`
`Deposition Transcript of Scott Serels, M.D., taken by plaintiffs on
`
`August 22, 2016
`
`JSN 2038
`
`Declaration of Matthew Rettig, M.D.
`
`JSN 2039
`
`Rettig CV
`
`JSN 2040
`
`Declaration of Richard Auchus, M.D., Ph.D.
`
`JSN 2041
`
`Auchus CV
`
`JSN 2042
`
`Declaration of Gerald Walter Chodak, M.D.
`
`JSN 2043
`
`Chodak CV
`
`JSN 2044
`
`Declaration of Christopher A. Vellturo, Ph.D.
`
`JSN 2045
`
`Vellturo CV
`
`JSN 2046
`
`Therasse et al., “New Guidelines to Evaluate the Response to
`
`Treatment in Solid Tumors,” J. Natl Cancer Inst., 92:205-216
`
`(2000)
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`Exhibit
`
`JSN 2047
`
`Description
`
`Stamey et al., “Prostate-Specific Antigen As A Serum Marker For
`
`Adenocarcinoma Of The Prostate,” NEJM, 317(15):909-916 (1987)
`
`JSN 2048
`
`Altman et al., “The Revised CONSORT Statement for Reporting
`
`Randomized Trials: Explanation and Elaboration,” Ann. Intern.
`
`Med., 134:663-694 (2001)
`
`JSN 2049
`
`Blackard, “Letters to the Editor,” Journal of Urology, 146(6):1621-
`
`1622 (1991)
`
`JSN 2050
`
`MedlinePlus, “ACTH stimulation test,” available at
`
`https://medlineplus.gov/ency/article/003696.htm, last visited Sept.
`
`30, 2016
`
`JSN 2051
`
`Dorin et al., “Diagnosis of Adrenal Insufficiency,” Ann. Inern.
`
`Med., 139:194-204 (2003)
`
`JSN 2052
`
`Grinspoon and Biller, “Clinical Review 62 Laboratory Assessment
`
`of Adrenal Insufficiency,” J. Clin. Endocrinol. And Metabolism,
`
`79(4):923-931 (1994)
`
`JSN 2053
`
`Lara and Meyers, “Treatment Options in Androgen-Independent
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`Exhibit
`
`Description
`
`Prostate Cancer,” Cancer Investigation, 17(2):137-144 (1999)
`
`JSN 2054
`
`Kuzel et al., “A Phase II Study of Continuous Infusion 5-
`
`Fluorouracil in Advanced Hormone
`
`Refractory Prostate Cancer,” Cancer, 72(6):1965-1968 (1993)
`
`JSN 2055
`
`Scher et al., “Bicalutamide for Advanced Prostate Cancer: The
`
`Natural Versus Treated History of Disease,” J. Clin. Oncology,
`
`15:2928-2838 (1997)
`
`JSN 2056
`
`Sternberg, “Hormone refractory metastatic prostate cancer,” Annals
`
`of Oncology, 3:331-335 (1992)
`
`JSN 2057
`
`Bubley et al., “Eligibility and Response Guidelines for Phase II
`
`Clinical Trials in Androgen-Independent Prostate Cancer:
`
`Recommendations From the Prostate-Specific Antigen Working
`
`Group,” J. Clin. Oncology, 17:3461-3467 (1999)
`
`JSN 2058
`
`Excerpts from Seifter, Concepts in Medical Physiology
`
`JSN 2059
`
`Petrylak et al., “Docetaxel and Estramustine Compared
`
`with Mitoxantrone and Prednisone for Advanced Refractory
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`Exhibit
`
`Description
`
`Prostate Cancer,” NEJM, 351:1513-1520 (2004)
`
`JSN 2060
`
`Marini et al., “The effect of adjuvant prednisone combined with
`
`CMF on patterns of relapse and occurrence of second malignancies
`
`in patients with breast cancer,” Annals of Oncology, 7:245-250
`
`(1996)
`
`JSN 2061
`
`Body, “Low-dose prednisone and increased risk of development of
`
`bone metastases,” Annals of Oncology, 7:643-645 (1996)
`
`JSN 2062
`
`Craft, “Eplerenone (Inspra), a new aldosterone antagonist for the
`
`treatment of systemic hypertension and heart failure,” BUMC
`
`Proceedings, 17:217-220 (2004)
`
`JSN 2063
`
`Small et al., “Antiandrogen Withdrawal Alone or in Combination
`
`With Ketoconazole in Androgen-Independent Prostate Cancer
`
`Patients: A Phase III Trial (CALGB 9583),” J. Clin. Oncology,
`
`22(6):1025-1033 (2004)
`
`JSN 2064
`
`Millikan, et al., “Randomized phase 2 trial of ketoconazole and
`
`ketoconazole/doxorubicin in androgen independent prostate
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`Exhibit
`
`Description
`
`cancer,” Urologic Oncology, 6:111-115 (2001)
`
`JSN 2065
`
`Farwell, et al., “Total Suppression of Cortisol Excretion by
`
`Ketoconazole in the Therapy of the Ectopic Adrenocorticotropic
`
`Hormone Syndrome,” American Journal of Medicine, 84:1063-
`
`1066 (1988)
`
`JSN 2066
`
`Mantero et al., “Long-term treatment of mineralocorticoid excess
`
`syndromes,” Steroids, 60:81-86 (1995)-
`
`JSN 2067
`
`Palmer, “Managing Hyperkalemia Caused by Inhibitors of the
`
`Renin–Angiotensin–Aldosterone System,” NEJ, 351:585-592
`
`(2004)
`
`JSN 2068
`
`Swartz and Dluhy, “Corticosteroids: Clinical Pharmacology and
`
`Therapeutic Use,” Drugs, 16:238-255 (1978)
`
`JSN 2069
`
`Seale and Compton, “Side-effects of corticosteroid agents,”, Med.
`
`J. of Australia, 144(3):139-142 (1986)
`
`JSN 2070
`
`FDA Press Release (2011)
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`Exhibit
`
`JSN 2071
`
`Description
`
`Ryan et al., “Abiraterone acetate plus prednisone versus placebo
`
`plus prednisone in chemotherapy-naive men with metastatic
`
`castration-resistant prostate cancer (COU-AA-302): final overall
`
`survival analysis of a randomised, double-blind, placebo-controlled
`
`phase 3 study,” Lancet Oncology, 16:152-160 (2015)
`
`JSN 2072
`
`Booth et al., “Oncology’s trials,” Nature Reviews, 2:609-610 (2003)
`
`JSN 2073
`
`Tokai July 26, 2016 Press Release
`
`JSN 2074
`
`Active/Ipsen April 16, 2015 Press Release
`
`JSN 2075
`
`Takeda June 19, 2014 Press Release
`
`JSN 2076
`
`Michaelson et al., “Randomized, Placebo-Controlled, Phase III
`
`Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in
`
`Progressive, Metastatic, Castration-Resistant
`
`Prostate Cancer,” J. Clin. Oncology, 31:1-8 (2013)
`
`JSN 2077
`
`OncoGenex (April 28, 2014) Press Release
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`Exhibit
`
`JSN 2078
`
`Description
`
`BMS Sept. 12, 2013 Press Release
`
`JSN 2079
`
`Carducci et al., “A Phase 3 Randomized Controlled Trial of the
`
`Efficacy and Safety of Atrasentan in Men With Metastatic
`
`Hormone-refractory Prostate Cancer,” Cancer, 110(9):1959-1966
`
`(2007)
`
`JSN 2080
`
`Antonarakis and Eisenberger, “Phase III Trials With Docetaxel-
`
`Based Combinations for Metastatic Castration-Resistant Prostate
`
`Cancer: Time to Learn From Past Experiences,” J. Clin. Oncology,
`
`31(14):1709-1712 (2013)
`
`JSN 2081
`
`Genentech March 12, 2010 Press Release
`
`JSN 2082
`
`Mulcahy, Medscape October 17, 2008 Press Release
`
`JSN 2083
`
`Novacea Form 8-K at 1.02
`
`JSN 2084
`
`ImmunoGen, Inc. Form 8-K, Item 8.01
`
`JSN 2085
`
`Sephton, et al., “Diurnal Cortisol Rhythm as a Predictor of Breast
`
`Cancer Survival,” Journal of National Cancer Institute,
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`Exhibit
`
`92(12):994-1000 (2000)
`
`Description
`
`
`JSN 2086
`
`White, P.C., “Synthesis and Metabolism of Corticosteroids,”
`
`Principles and Practice of Endocrinology and Metabolism, Ed.
`
`Kenneth L. Becker, Philadelphia: Lippincott Williams & Wilkins,
`
`2001, Chapter 72, 704-714
`
`JSN 2087
`
`White, P.C., “Synthesis and Metabolism of Corticosteroids,”
`
`Principles and Practice of Endocrinology and Metabolism, Ed.
`
`Kenneth L. Becker, Philadelphia: Lippincott Williams & Wilkins,
`
`2001, Chapter 73, 714-719
`
`JSN 2088
`
`White, P.C., “Synthesis and Metabolism of Corticosteroids,”
`
`Principles and Practice of Endocrinology and Metabolism, Ed.
`
`Kenneth L. Becker, Philadelphia: Lippincott Williams & Wilkins,
`
`2001, Chapter 78, 751-764
`
`JSN 2089
`
`NCI - SEER Stat Fact Sheets: Prostate Cancer
`
`JSN 2090
`
`Tucker et al., “Reversible Adrenal Insufficiency Induced by
`
`Ketoconazole,” JAMA, 253(16):2413-2414 (1985)
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`Exhibit
`
`JSN 2091
`
`Description
`
`What You Need to Know About Prostate Cancer, NIH Publication
`No. 12-1576 (2012)
`
`JSN 2092
`
`Understanding Zytiga Users “Urologist Success” Qualitative
`Research, January 2014
`
`JSN 2093
`
`Patient Affordability, 2013-11-06
`
`JSN 2094
`
`Zytiga ATU – Wave 4,
`
`2015-10-20
`
`JSN 2095
`
`Zytiga Usage – prednisone information
`
`JSN 2096
`
`Zytiga Usage – total promo spend
`
`JSN 2097
`
`ICR – “Abiraterone: a story of scientific innovation and
`
`commercial partnership”
`
`JSN 2098
`
`ACS – “What is Prostate Cancer? Topics”
`
`JSN 2099
`
`Cancer.Net - September 8, 2014 “Treatment of Metastatic
`
`CastrationResistant Prostate Cancer”
`
`JSN 2100
`
`CDC – “Prostate Cancer”
`
`JSN 2101
`
`J&J May 21, 2009 Press Release
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`Exhibit
`
`JSN 2102
`
`Description
`
`Mayo Clinic – Prednisone and other corticosteroids
`
`JSN 2103
`
`Medical Dictionary – refractory cancer
`
`JSN 2104
`
`NCI – Docetaxel
`
`JSN 2105
`
`NCI – Metastatic Cancer
`
`JSN 2106
`
`Orange Book – Xofigo
`
`JSN 2107
`
`Orange Book – Xtandi
`
`JSN 2108
`
`Orange Book – Jevtana
`
`JSN 2109
`
`Hotte and Saad, “Current management of castrate-resistant prostate
`
`cancer,” Current Oncology, 17(2):S72-S79 (2010)
`
`JSN 2110
`
`J&J January 22, 2013 Press Release – Johnson & Johnson Reports
`
`2012 Fourth-Quarther and Full-Year Results
`
`JSN 2111
`
`Deposition of DeForest McDuff, taken by plaintiffs on September
`
`1, 2016
`
`JSN 2112
`
`Reserved
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`Exhibit
`
`Description
`
`
`JSN 2113
`
`Standing Protective Order
`
`JSN 2114
`
`Redline of Standing Protective Order
`
`JSN 2115
`
`Redacted Expert Report of Christopher Vellturo
`
`JSN 2116
`
`Williams, “Discontinued Drugs in 2007: oncology drugs,” Expert
`
`Opinion on Investigational Drugs, 17(12):1791-1816 (2008)
`
`JSN 2117
`
`Williams, “Discontinued Drugs in 2008: oncology drugs,” Expert
`
`Opinion on Investigational Drugs, 18(11):1581-1594 (2009)
`
`JSN 2118
`
`Declaration of Johann S. De Bono
`
`JSN 2119
`
`Redacted version of Expert Declaration of Matthew Rettig, M.D.
`
`JSN 2120
`
`Declaration of Alyssa Monsen in Support of Motion to Appear Pro
`
`Hac Vice
`
`JSN 2121
`
`2016/10/18 Email from Isaac Olson to William Hare
`
`JSN 2122
`
`2016/11/10 (DI 239)-Opinion on Markman Patent Claim
`
`Construction (DNJ)
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`Exhibit
`
`JSN 2123
`
`Description
`
`2016/14/10 (DI 240)-Order on Markman Patent Claim Construction
`
`(DNJ)
`
`JSN 2124
`
`Deposition Transcript of Mark J. Ratain, M.D., taken by Patent
`
`Owner on January 23, 2017
`
`JSN 2125
`
`Deposition Transcript of Richard Dorin, M.D., taken by Patent
`
`Owner on January 19, 2017
`
`JSN 2126
`
`2017-01-17 PTAB E2E Filing Notification
`
`JSN 2127
`
`Deposition Transcript of Scott R. Serels., taken by Patent Owner on
`
`January 21, 2017
`
`
`
`Dated: January 30, 2017
`
`Respectfully submitted,
`
`By: /Dianne B. Elderkin/
`Dianne B. Elderkin (Reg. No. 28,598)
`delderkin@akingump.com
`Barbara L. Mullin (Reg. No. 38,250)
`bmullin@akingump.com
`Ruben H. Munoz (Reg. No. 66,998)
`rmunoz@akingump.com
`AKIN GUMP STRAUSS HAUER &
`FELD LLP
`Two Commerce Square
`2001 Market Street, Suite 4100
`Philadelphia, PA 19103
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`
`
`
`
`Tel: (215) 965-1200
`Fax: (215) 965-1210
`
`David T. Pritikin (pro hac vice)
`Bindu Donovan (pro hac vice)
`Paul J. Zegger (Reg. No. 33,821)
`Todd L. Krause (Reg. No. 48,860)
`S. Isaac Olson (pro hac vice)
`Alyssa B. Monsen (pro hac vice)
`SIDLEY AUSTIN LLP
`787 Seventh Avenue
`New York, NY 10019
`Tel.: (212) 839-5300
`Fax: (212) 839-5599
`ZytigaIPRTeam@sidley.com
`Counsel for Patent Owner
`
`
`
`
`IPR2016-00286
`Patent 8,822,438
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Janssen
`
`Oncology, Inc.’s Updated Exhibit List was served on counsel of record on January
`
`30, 2017 by filing this document through the End-to-End System, as well as
`
`delivering a copy via electronic mail to counsel of record for the Petitioners and
`
`Patent Co-Owner at the following addresses:
`
`William Hare - bill@miplaw.com
`Gabriela Materassi - materassi@miplaw.com
`
`Teresa Stanek Rea - TRea@Crowell.com
`Shannon M. Lentz - SLentz@Crowell.com
`
`Anthony C. Tridico - anthony.tridico@finnegan.com
`Jennifer H. Roscetti - jennifer.roscetti@finnegan.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`By: /Dianne B. Elderkin/
`Dianne B. Elderkin
`Registration No. 28,598
`Counsel for Patent Owner
`
`
`
`Date: Jan. 30, 2017
`
`
`
`
`
`
`
`
`
`
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
